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Abstract: Evidence suggests a role of long chain polyunsaturated fatty acids (LC-PUFA), in which
animal foods are especially rich, in optimal neural development. The LC-PUFAs docosahexaenoic
acid (DHA) and arachidonic acid, found in high concentrations in the brain and retina, have potential
beneficial effects on cognition, and motor and visual functions. Phenylketonuria (PKU) is the most
common inborn error of amino acid metabolism. The treatment of PKU consists of a phenylalanine-free
diet, which limits the intake of natural proteins of high biological value. In this systematic review, we
summarize the available evidence supporting a role for LC-PUFA supplementation as an effective
means of increasing LC-PUFA levels and improving visual and neurocognitive functions in PKU
patients. Data from controlled trials of children and adults (up to 47 years of age) were obtained by
searching the MEDLINE and SCOPUS databases following Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. For each selected study, the risk of bias was
assessed applying the methodology of the Cochrane Collaboration. The findings indicate that DHA
supplementation in PKU patients from 2 weeks to 47 years of age improves DHA status and decreases
visual evoked potential P100 wave latency in PKU children from 1 to 11 years old. Neurocognitive
data are inconclusive.
Keywords: arachidonic acid; cognitive function; docosahexaenoic acid; long-chain polyunsaturated
fatty acids; phenylketonuria; visual function
1. Introduction
Phenylketonuria (PKU; OMIM 261600) is an inborn error of phenylalanine (Phe) metabolism caused
by an inherited deficiency in L-phenylalanine-4-hydroxylase (PAH; EC 1.14.16.1) activity, leading to
elevated levels of Phe in body fluids [1]. Of patients with high phenylalanine concentrations, 98% have a
defect in PAH and 1–2% in tetrahydrobiopterin metabolism. Children with PKU diagnosed by newborn
screening who begin dietary treatment during the neonatal period usually show normal neurological
development [2,3]. However, these patients may have lower intelligence quotients [4] and exhibit mild
neuropsychological disturbances including impaired motor skills, visual function, attention, inhibition,
and memory [5,6], especially when compared with non-phenylketonuric siblings [7] and healthy
individuals [8,9]. PKU treatment consists of lifelong restriction of Phe intake by limiting the amount of
natural protein in the diet, combined with administration of a Phe-free amino-acid mixture [10]. More
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recently, a synthetic form of tetrahydrobiopterin (6R-BH4) has been used to treat selected patients
who have moderate forms of PKU and respond to the BH4 loading test [11,12]. Owing to a tendency
to exclude protein-rich animal food from their diet, micronutrient deficiencies are common in PKU
patients [13–15].
Meat and fish are the main sources of long-chain polyunsaturated fatty acids (LC-PUFA) in
humans, and although they are produced endogenously, dietary intake is the key determinant of
LC-PUFA levels [16]. Docosahexaenoic acid (DHA) and arachidonic acid (AA) are the most important
LC-PUFAs of the n-3 and n-6 series, respectively [17]. Both are structural components of cell membranes
and influence their biological functions, including enzymatic activity, transport through ion channels,
and signal transduction [18], especially in the nervous system and the retina [19]. Incorporation of
DHA and AA in these tissues during the pre- and postnatal periods has been correlated with visual,
cognitive, and motor functions in humans [20–22].
The low-Phe diet of PKU patients has been linked to insufficient blood levels of LC-PUFAs,
which may contribute to the mild neurological, cognitive, and visual alterations described in these
patients [23]. However, to date no conclusive evidence supports a link between the PKU diet, the
LC-PUFA profile and the clinical status of PKU patients [24]. In this systematic review, we present a
comprehensive overview of evidence from clinical trials assessing a correlation between the PKU diet,
LC-PUFA status, and neurocognitive and visual functions.
2. Methods
This review was conducted following the guidelines for Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [25] and was registered in the International Prospective
Register of Systematic Reviews (PROSPERO) with the number CRD42019133315. The review question,
which was formulated following the PICOS (Population, Intervention, Comparison, Outcomes and
Settings) criteria [26] (Table 1), was as follows: Does LC-PUFA supplementation influence visual and
neurocognitive functions in patients with phenylketonuria?
Table 1. PICOS (Population, Intervention, Comparison, Outcomes and Settings) criteria [26] for
the inclusion of studies evaluating the effects of long-chain polyunsaturated fatty acids (LC-PUFA)
supplementation in phenylketonuria patients.
Parameter 1 Inclusion Criteria
Population Patients with phenylketonuria
Intervention Controlled LC-PUFA intake
Comparison Non-exposed control group
Outcome Visual and neurocognitive functions and fatty acid levels
Setting Controlled trials
1 PICOS criteria [26].
2.1. Inclusion and Exclusion Criteria
Studies were selected applying the following inclusion criteria: all controlled studies, randomized
or not, of patients with PKU of any age and ethnicity that were published between 1 January 1995 and
1 April 2019. Studies in which LC-PUFA supplementation was administered parenterally and those
lacking a control group that did not receive LC-PUFA supplementation were excluded.
2.2. Intervention Types
Studies were not restricted according to the duration of supplementation or the type or dose of
LC-PUFAs administered. All studies in which patients received oral LC-PUFA supplementation and
the effects were compared with a non-supplemented group were considered for inclusion.
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2.3. Primary Outcome Measures
Visual evoked potential (VEP) variables, specifically alterations in P100 wave and P1 peak latencies
(in ms), were the primary outcome measures used to assess the effects of LC-PUFA supplementation
on visual function. For the assessment of neurocognitive function, data from any study that included
some form of evaluation of psychomotor development were considered. Circulating and erythrocyte
lipid levels and changes in lipid levels (mg/L, mmol/L, or % change) after supplementation were
considered valid measures for the assessment of effects on lipid status.
2.4. Literature Search
The PUBMED and SCOPUS databases were searched using the MeSH terms “Fatty
Acids, Unsaturated” and “Phenylketonurias”. “Fatty Acids, Unsaturated” (Mesh Terms) AND
“Phenylketonurias” (Mesh Terms) was the search strategy used in PUBMED. SCOPUS was searched
using the following formula: “Fatty acids” AND “Phenylketonurias”, excluding results from
animal studies.
2.5. Study Selection
Two authors (MJDC and CDL) independently selected studies from the 33 articles reviewed in
full. In cases in which there was a lack of consensus regarding selection, discrepancies were arbitrated
by MLC and RL. Nine articles [27–35] were ultimately selected for inclusion in the review.
2.6. Data Extraction
The following data were extracted from each study: publication year; number of participants
by sex; age; study type; intervention characteristics. Data on study duration, outcomes, results, and
conclusions were separately extracted by two investigators. Any discrepancies in opinions were
arbitrated by MLC and RL.
2.7. Assessment of Risk of Bias
Following the methodology of the Cochrane Collaboration, London, UK [36], two evaluators
independently studied the risks of bias. The articles were analyzed individually, and the corresponding
risk of bias was classified as high, uncertain, or low depending on the risk of selection bias (random
sequence generation, allocation concealment), performance bias (blinding of participants and personnel),
detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting
bias (selective reporting), and other forms of bias. A third and a fourth reviewer arbitrated in cases of
discrepancies of opinion. We also evaluated the general risk of bias in the group of articles included in
the systematic review, expressed as a percentage of articles that present a risk of specific bias in relation
to the total number of studies included.
3. Results
The results of each step of the bibliographic search are shown in Figure 1. Of the 84 results from
the first search (PUBMED, 53; SCOPUS, 30; other sources, 1), 27 duplicate articles were excluded.
Twenty-four articles were excluded after revision of the abstract. Of the 33 articles considered for
evaluation of the complete text, nine articles were ultimately included in the systematic review [27–35].
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Figure 1. Flow chart depicting the literature search process. 
Tables 2–4 show the main characteristics of the selected clinical trials. Publication dates range 
from 1995 to 2017. Only one [35] of the nine articles included was published before the year 2000. The 
combined study population of the nine clinical trials included in this review was 419 individuals, 365 
(87.1%) of whom had phenylketonuria. Only two studies included a healthy control group [29,33] 
and the remaining seven, a PKU control group [27,28,30–32,34,35]. Ages ranged from 2.1 weeks to 47 
years. The mean sample size was 46 ± 27 participants (range, 20–109). The median intervention period 
was 6 months (range, 3–12 months). Supplementation consisted of a phenylalanine-free LC-PUFA-
supplemented infant formula [30–32] or DHA [27,28] or fish-oil [29,33–35] capsules. In one study [32], 
no information on the DHA supplementation dose was provided. In all other studies, the DHA dose 
ranged from 0.1 to 15 mg/kg/day. In four studies, supplementation consisted of a combination of 
omega 6 and omega 3 [30–32,34], with omega 6 to omega 3 ratios ranging from 1:1 to 3:1. 
3.1. LC-PUFA Supplementation and Circulating and Erythrocyte Lipids 
Changes in circulating and erythrocyte lipids were evaluated in seven of the nine studies 
[27,28,30–32,34,35] (Table 2), all of which reported significant differences in DHA levels in LC-PUFA-
supplemented groups versus controls. Of those seven trials, five [27,28,32,34,35] reported higher 
levels of DHA in the LC-PUFA-supplemented group, while two trials concerning LC-PUFA 
supplementation in infants [30,31] reported a significantly lower decrease in DHA levels compared 
with controls. Four of the articles [27,28,30,35] evaluated DHA levels in plasma and four [28,31,32,34] 
in erythrocyte lipids. Only one study [28] evaluated DHA levels in both plasma and erythrocyte 
lipids. Of the two studies in which cholesterol and triglyceride levels were measured [27,35], the 
study by Demmelmair et al., in which patients received the lower DHA dose [27], reported no 
differences in these variables between groups, while the other [35] reported significantly lower 
triglyceride levels in the LC-PUFA-supplemented group. 
3.2. LC-PUFA Supplementation and Visual Function 
Four of the studies included in our review provided VEP data [27,31,33,34] (Table 3). All 
measured P100 wave latency (Pattern VEP), and one [31] also measured the P1 peak (Flash VEP). 
Two of the four studies in which the highest dose (15 mg/kg) of DHA [33,34] was administered 
reported significant decreases in P100 wave latency in the supplementation group, which received 
DHA capsules in both cases. The two remaining studies [27,31], one [31] in which newborns were 
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Tables 2–4 show the main characteristics of the selected clinical trials. Publication dates range
from 1995 to 2017. Only one [35] of the nine articles included was published before the year 2000. The
combined study population of the nine clinical trials included in this review was 419 individuals, 365
(87.1%) of whom had phenylketonuria. Only two studies included a healthy control group [29,33]
and the remaining seven, a PKU control group [27,28,30–32,34,35]. Ages ranged from 2.1 weeks to
47 years. The ean sa ple size as 46 ± 27 participants (range, 20–109). The median intervention
period was 6 months (range, 3–12 months). Supplementation consisted of a phenylalanine-free
LC-PUFA-supplemented infant formula [30–32] or DHA [27,28] or fish-oil [29,33–35] capsules. In one
study [32], no information on the DHA supplementation dose was provided. In all other studies,
the DHA dose ranged fro 0.1 to 15 mg/kg/day. In four studies, supplementation consisted of a
combination of omega 6 and omega 3 [30–32,34], with o ega 6 to omega 3 ratios ranging from 1:1 to
3:1.
3.1. LC-PUFA Supplementation and Circulating and Erythrocyte Lipids
Changes in circulating and erythrocyte lipids were evaluated in seven of the nine
studies [27,28,30–32,34,35] (Table 2), all of which reported significant differences in DHA levels in
LC-PUFA-supplemented groups versus controls. Of those seven trials, five [27,28,32,34,35] reported
higher levels of DHA in the LC-PUFA-supplemented group, while two trials concerning LC-PUFA
supplementation in infants [30,31] reported a significantly lower decrease in DHA levels compared
with controls. Four of the articles [27,28,30,35] evaluated DHA levels in plasma and four [28,31,32,34]
in erythrocyte lipids. Only one study [28] evaluated DHA levels in both plasma and erythrocyte lipids.
Of the two studies in which cholesterol and triglyceride levels were measured [27,35], the study by
Demmelmair et al., in which patients received the lower DHA dose [27], reported no differences in
these variables between groups, while the other [35] reported significantly lower triglyceride levels in
the LC-PUFA-supplemented group.
3.2. LC-PUFA Supplementation and Visual Function
Four of the studies included in our review provided VEP data [27,31,33,34] (Table 3). All measured
P100 wave latency (Pattern VEP), and one [31] also measured the P1 peak (Flash VEP). Two of the four
studies in which the highest dose (15 mg/kg) of DHA [33,34] was administered reported significant
decreases in P100 wave latency in the supplementation group, which received DHA capsules in both
cases. The two remaining studies [27,31], one [31] in which newborns were supplemented with formula
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and the other one [27] with 0.1–7 mg/kg of DHA supplementation, reported no significant differences
in visual function between groups.
3.3. LC-PUFA Supplementation and Neurocognitive Function
Neurocognitive function was evaluated in four studies [27–29,31] (Table 4): three studies [27,28,31]
assessed the cognitive area and two studies [27,29] the motor function. Only one [29] reported
significant differences in psychomotor development between supplemented and non-supplemented
groups. There was considerable variability among these four studies in terms of age and outcomes.
Ages ranged from 20 ± 6.9 weeks in the study by Agostoni et al. [31] to 12–47 years in the study by Yin
et al. [28].
There was also considerable heterogeneity regarding the scales used to evaluate cognition: one
study [28] assessed verbal ability using the Peabody picture vocabulary test, executive function using
the Delis Kaplan executive function system and processing speed using the Woodcock–Johnson III tests
of cognitive ability and achievement; another [27] calculated the intellectual quotient using Raven’s
progressive matrices; and a third study [31] assessed the coefficient of development using the Bayley
test. The two studies that evaluated motor function [27,29] both used the Rostock–Oseretzky scale.
3.4. Risk-of-Bias Assessment
For all studies included in our review, we concluded that there was a low risk of selection bias
(allocation concealment) and an unclear risk of reporting bias (selective reporting). The percentage
of studies for which the risk of different forms of bias was considered low was as follows: attrition
bias (incomplete outcome data), 89%; selection bias (random sequence generation), 66%; performance
bias (blinding of participants and personnel), 66%; detection bias (blinding of outcome assessment),
55%. We concluded that there was a risk of other forms of bias in 55% of studies, due to a lack of
standardized protocols in three multicenter studies [27,31,32] and the lack of a control group composed
of non-LC-PUFA-supplemented PKU patients in two studies [29,33].
The study for which the risk of biased results was greatest was that of Cleary et al. [32]; a
multicenter study for which no standardized protocol was described. The risk of attrition bias was also
high for this study, given the omission of an intention-to-treat analysis. The risk of bias was lowest for
the studies by Koletzko et al. [29] and Yin et al. [28].
Additional information on the risk-of-bias analysis (risk-of-bias graph and summary) is provided
in the Supplementary Materials Figures S1 and S2.
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Table 2. Effects of LC-PUFA supplementation on circulating and erythrocyte lipids in 299 phenylketonuria patients in controlled trials.











RCT (6 months) Change in plasma lipid
concentration
DHA (mg/L): IG1, 5.1 ± 10.3; IG2, 3.19.5 ± 13.6; CG, 0.0 ± 9.1
Significant increase in
DHA levels
TC (mmol/L): IG1, 0.0 ± 0.5; IG2, 0.1 ± 0.5; CG, −0.1 ± 0.6
HDL (mmol/L): IG1, 0.0 ± 0.3; IG2, 0.0 ± 0.2; CG, −0.0 ± 0.3
LDL (mmol/L): IG1, 0.2 ± 0.5; IG2, 0.1 ± 0.5; CG, −0.3 ± 1.2
TG (mmol/L): IG1, 0.0 ± 0.5; IG2, −0.1 ± 0.5; CG, −0.1 ± 0.6




Erythrocyte DHA (weight % erythrocyte FA): IG, 5.82 ± 1.26; CG, 2.35 ±
0.78
Koletzko et al. (2007)
[30]
21 (8 F) 2.1 ± 0.9 weeks
Test-treatment formula (DHA,
0.23 g/100 g FA. RCT (12 months) Plasma phospholipid FA DHA (weight % FA): IG, 3.08 ± 0.1; CG, 1.52 ± 0.19 Significant less decline
of DHA levelsOmega 6: omega 3 ratio, 2:1)
Agostoni et al. (2006)
[31]
42 (22 F) 20 ± 6.9 weeks
Test-treatment formula (DHA,
0.3 g/100 g FA.
RCT (12 months)






IG, −22%; CG, −64%
% change AA:
Omega 6: omega 3 ratio, 2.5:1
IG, –5%; CG, –19%




2.8 g/100 g. RCT (20 weeks)
Median change in LC-PUFA
concentration in erythrocyte
MB phospholipids
% change DHA: IG, +19%; CG, +0.5% Significant increase in
DHA levelsOmega 6: omega 3 ratio, 3:1) % change AA: IG, +0.5%; CG, +7.6%
Agostoni et al. (2000)
[34]
20 (9 F)
10.7 ± 2.4 years (IG)





Erythrocyte PC (weight % FA): EPA: IG, 0.1 ± 0.07; CG, 0.1 ± 0.04
Significant increase of
DHA levels
DHA: IG, 0.9 ± 0.3; CG, 0.4 ± 0.2. AA: IG, 5.39 ± 1.16; CG, 5.83 ± 0.98
AA:DHA ratio, 1:110.5 ± 2.8 years (CG)
Erythrocyte PEA (weight % FA): EPA: IG, 0.3 ± 0.1; CG, 0.2 ± 0.1 DHA: IG,
3.7 ± 1.7; CG, 1.3 ± 0.9. AA: IG, 16.1 ± 5.2; CG, 14.5 ± 7.3
Agostoni et al. (1995)
[35] 21
5–10 years
Fish oil capsules (DHA,
15 mg/kg/day; EPA,
22.5 mg/kg/day)
RCT (6 months) Plasma lipid concentration
TC (mmol/L): IG, 3.12 ± 0.67; CG, 3.41 ± 0.28
Significant decrease in
triglycerides and
increase in n-3 LC-PUFA
levels
HDL (mmol/L): IG, 1.06 ± 0.18; CG, 1.18 ± 0.23
LDL (mmol/L): IG, 1.75 ± 0.72; CG, 1.73 ± 0.49
TG (mmol/L): IG, 0.68 ± 0.16; CG, 1.09 ± 0.47
LC-PUFA (weight % FA). EPA: IG, 1.96 ± 0.79; CG, 0.27 ± 0.06
DHA: IG, 2.94 ± 0.88; CG, 0.73 ± 0.08; AA: IG, 5.39 ± 1.16; CG, 5.83 ± 0.98
AA, arachidonic acid; CG, control group; CT, controlled trial; DHA, docosahexaenoic acid (22:6, n-3); EPA, eicosapentaenoic acid (20:5, n-3); F, female; FA, fatty acid; HDL, high density
lipoprotein cholesterol; IG, intervention group; LC-PUFA, long chain polyunsaturated fatty acid; LDL, low-density lipoprotein cholesterol; MB, membrane; PC, phosphatidylcholine;
PEA, phosphatidylethanolamine; RCT, randomized controlled trial; TC, total cholesterol;. TG, triglyceride. 1 Values (at entry) represent the range or the mean ± SD, as reported in the
corresponding article. 2 Values represent the mean or mean ± SD, as reported in the corresponding article.
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Table 3. Effects of LC-PUFA supplementation on visual function in 237 subjects in controlled trials.
Reference n Age 1 Intervention
Type and Duration of
Intervention Outcome Measure Results
2 Conclusion
Demmelmair et al.
(2018) [27] 109 5–13 years
DHA capsules (IG1, 0.1–1.8 mg/kg/day;
IG2, 1.9–7 mg/kg/day) RCT—6 months
Change in P100 wave
latency (ms)
Pattern-reversal. 15: IG1,
0.5 ± 8.7; IG2, −0.6 ± 4.7;




42 (22 F) 20 ± 6.9 weeks
Test-treatment formula (DHA, 0.3 g/100 g
FA. RCT—12 months
P100 wave (pattern
VEP) and P1 peak (flash
VEP) latencies (ms)
Pattern-reversal: IG, 120 ±
24; CG, 107 ± 8 No significant differences
Omega 6: omega 3 ratio, 2.5:1) Flash: IG, 108 ± 15; CG, 115
± 24
Beblo et al. (2001)
[33]
66 (34 F) 6.6 ± 1.5 years (CG)
Fish oil capsules (DHA, 15 mg/kg/day;
EPA, 22.5 mg/kg/day)
CT—3 months Change in P100 wave
latency No data
Significant decrease in P100




10.7 ± 2.4 years (IG) Fish oil capsules (DHA, 15 mg/kg/day)
RCT—12 months P100 wave latency (ms)
Pattern-reversal. 60’: IG,
104 ± 4; CG, 109 ± 9. 15’: IG,
107 ± 6; CG, 118 ± 11. Significant decrease in P100
wave latency (15’, 2 Hz-1 J)Flash. 1 Hz-2 J: IG, 113 ± 10;
CG, 114 ± 8.10.5 ± 2.8 years (CG)
AA:DHA ratio, 1:1
2 Hz-1 J: IG, 111 ± 12; CG,
121 ± 8
AA, arachidonic acid; CG, control group; CT, controlled trial; DHA, docosahexaenoic acid (22:6, n-3); F, female; EPA, eicosapentaenoic acid (20:5, n-3); FA, fatty acids; IG, intervention
group; RCT, randomized controlled trial; VEP, visual evoked potentials. 1 Values (at entry) represent the range or mean ± SD, as reported in the corresponding article. 2 Values represent
the mean ± SD, as reported in the corresponding article.
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Table 4. Effects of LC-PUFA supplementation on neurocognitive function in 238 subjects in controlled trials.
Reference n Age 1 Intervention
Type and Time of




5–13 years DHA capsules (IG1, 0.1–1.8 mg/kg/day;
IG2, 1.9–7 mg/kg/day) RCT—6 months
Changes in motometric Rostock–Oseretzky
scale and Raven´s progressive matrices
Rostock–Oseretzky scale:
IG1, 4.2 ± 6.3; IG2, 0.8 ± 9.1;
CG, 2.9 ± 7.0
No significant differences
Raven’s progressive
matrices: IG1, 2.2 ± 15.8;
IG2, 1.6 ± 13.8; CG, 9.5 ±
13.5
Yi et al. (2011) [28] 33 (33 F) 12–47 years DHA capsules (10 mg/kg/day) RCT—4.5 months
Verbal ability (Peabody picture vocabulary test,
third edition), executive function
(Delis-Kaplan executive function system), and
cognitive processing speed
(Woodcock–Johnson III tests of cognitive
ability and achievement)
Cognitive processing speed,
factor score: IG, 98.8 ± 5.3;
CG, 101 ± 5.4 No significant differences
Cognitive inhibition: IG,
11.3 ± 1.5; CG, 11.4 ± 1.5
Cognitive flexibility: IG,
11.1 ± 1.4; CG, 10.8 ± 1.4
Koletzko et al.
(2009) [29] 54
6.3 ± 0.6 years Fish oil capsules (DHA, 15 mg/kg/day;
EPA, 22.5 mg/kg/day)
CT—3 months Changes in motometric Rostock–Oseretzky
scale
No data
Significant improvement in fine motor skills (especially coin
sorting), dynamic balance, and total score in intervention groupCG, healthy children
Agostoni et al.
(2006) [31]
42 (22 F) 20 ± 6.9 weeks
Test-treatment formula (DHA, 0.3 g/100 g
FA. RCT—12 months
Mental and psychomotor development (Bailey
test, second edition)
Mental development: IG,
92.67 ± 16.02; CG, 93.19 ±
16.60 No significant differences
Physical development: IG,
92 ± 13.32; CG, 97.69 ± 15.57Omega 6: omega 3 ratio, 2.5:1)
AA, arachidonic acid; CG, control group; CT, controlled trial; DHA, docosahexaenoic acid (22:6, n-3); EPA, eicosapentaenoic acid (20:5, n-3); F, female; FA, fatty acids; IG, intervention
group; LC-PUFA, long chain polyunsaturated fatty acid; RCT, randomized controlled trial; VEP, visual evoked potentials. 1 Values (at entry) represent the range, mean, or mean ± SD, as
reported in the corresponding article. 2 Values represent the mean ± SD, as reported in the corresponding article.
Nutrients 2019, 11, 1537 9 of 14
4. Discussion
This systematic review of controlled trials regarding LC-PUFA supplementation in children
and adults with PKU reveals that the addition of DHA at doses ≥10 mg/kg/day to the patient’s
Phe-restricted diet decreases VEP latencies. However, no conclusive evidence supports a relationship
between LC-PUFA supplementation and neurocognitive outcomes in these patients.
DHA and AA are the most important LC-PUFAs of the n-3 and n-6 series, respectively. These key
structural components of neuronal cell membranes are of crucial importance for brain development
and retinal function [37]. In randomized clinical trials, LC-PUFA supplementation is associated with
improved visual and cognitive maturation in full-term and, in particular, preterm infants [38–40].
These outcomes in preterm infants may be linked to the greater predisposition of these children to
LC-PUFA deficiency due to fetal accretion of DHA (which usually occurs during the third trimester),
an inability to convert precursor fatty acids to DHA, and low postnatal DHA intake [41].
PKU patients are another population at risk of LC-PUFA deficiency; the typical Phe-restricted
diets of these patients provide low amounts of animal products, which are the main source of
LC-PUFAs [42,43]. Moreover, excess Phe is catabolized to phenylpyruvate and phenyllactate, which
are reported to inhibit endogenous synthesis of DHA and AA [44]. A 2013 systematic review and
meta-analysis of nine case control studies and six randomized controlled trials concluded that PKU
patients have significantly lower levels of both DHA and AA in all biomarkers studied than healthy
controls [24]. In line with this suboptimal LC-PUFA status in PKU patients, studies of children with
amino acid metabolism disorders have described reduced LC-PUFA intake (a consequence of dietary
protein restriction) and lower plasma and erythrocyte membrane concentrations of DHA than healthy
controls [45–47]. The results of studies of AA status in these patients are inconclusive (ranging from
normal to reduced), suggesting that endogenous synthesis may be sufficient to ensure adequate AA
status in some cases [48].
The findings of this systematic review indicate that DHA supplementation in PKU patients
significantly increases DHA levels in plasma and/or erythrocyte membranes [27–35]. It should be
noted that erythrocyte fatty acid composition yields more information regarding long-term LC-PUFA
status and is less influenced by fasting, appearing to be a more valuable biomarker [49,50]. While the
most commonly administered dose of DHA was 10–15 mg/kg/day, significant increases in DHA levels
were observed even with lower doses (0.1–7 mg/kg/day) [27]. There are insufficient data to define an
optimal LC-PUFA supplementation dose for PKU patients of different age groups, and optimal DHA
intake in infants and children remains a topic of debate according to both the ESPGHAN Committee on
Nutrition and The European Food Safety Authority Panel on Dietetic Products, Nutrition and Allergies
(NDA). Despite the lack of appropriate data on which to base dietary reference values for pediatric
patients, the aforementioned organizations have proposed an intake of 100 mg/day for patients aged
6–24 months and 250 mg/day for those aged 2 years and older [51].
VEP testing was conducted to assess central nervous system (CNS) function in four of the studies
included in this review [27,31,33,34]. VEP is widely used in studies of neural maturation as it provides
a sensitive means of assessing the function of a major CNS pathway. P100 wave latency is considered
the most reliable clinical indicator, as is the variable least affected by technical factors and the degree
of patient cooperation [52]. Longer VEP latencies, which are observed in PKU patients not receiving
LC-PUFA supplementation [52], indicate a lower speed of information processing from the retina to
the visual cortex. It should be noted that the controlled trials (CTs) and randomized controlled trials
(RCTs) in which shorter P100 wave latencies were observed after intervention were those in which
the patients received higher doses of DHA (10–15 mg/kg/day) [33,34]. In the two RCTs [27,31] that
reported no differences in VEP latencies after LC-PUFA supplementation, patients received lower
(0.1–7 mg/kg/day) or uncontrolled doses (i.e., a LC-PUFA-supplemented, Phe-free formula) of DHA. In
the latter study [31], higher levels of DHA in erythrocyte membranes were significantly correlated with
a shorter P100 wave latency after adjustment for age. This observation suggests that the LC-PUFA
intake of these patients was irregular and, in many cases, insufficient to alter the clinical outcome.
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None of the studies included in this review specifically evaluated retinal function. However, a
2013 study [53] assessed visual function in PKU patients using a comprehensive ophthalmological
test battery. Electroretinography (ERG), which allows for objective measurement of retinal function,
revealed that PKU patients showed abnormalities in scotopic and photopic ERG amplitudes and
latencies not observed in healthy individuals. It should be noted that this pattern of ERG alterations
has also been described in animal models of LC-PUFA depletion and is likely related to abnormal DHA
metabolism in photoreceptor membranes [54–56].
Evidence suggests that LC-PUFA supplementation may improve neurocognitive function,
including motor skills [29], in PKU patients. Children with early-treated PKU can present structural
alterations in cerebral white matter myelin [57–59] that may be associated with high Phe levels, but
also with low DHA concentrations. However, because beneficial effects were reported in only one
CT [29], and given the considerable variability across the studies included in this review in terms of the
dose used, form of supplementation, functional outcome measures, and neurocognitive scales used,
the available evidence is inconclusive. Previous reviews that have assessed the effects of LC-PUFA
supplementation on cognitive performance in children and adults without PKU [60–63] have reported
similarly inconclusive findings, in large part due to the marked heterogeneity in the interventions and
outcome measures used.
The duration of the intervention is another important variable to consider when examining the
functional effects of LC-PUFA supplementation. In their study of the effects of DHA administration
in pediatric PKU patients and healthy controls, Agostoni et al. [64] found that P100 wave latencies
and DHA status, both of which had improved in the PKU group during the intervention, returned to
baseline levels 3 years after treatment discontinuation.
When evaluating the risk of bias for each of the studies included in this systematic review, not all
forms of bias should be considered equally important. For example, because LC-PUFA levels and VEP
latencies are objective measures, the selected studies are less likely to be affected by performance bias.
Besides that, the reporting bias is unclear in all articles included, so the main forms of bias to consider
in our review are selection bias, attrition bias, and detection bias.
Future studies should consider using standardized neurocognitive assessment scales and doses
and durations of DHA supplementation in order to determine the tissue levels of DHA necessary
to achieve significant homogenous clinical improvements. Moreover, data on the clinical course
of patients who discontinue DHA supplementation could be particularly valuable, since the effects
of DHA may disappear after discontinuation. Specifically, adjustment of these data for age would
enable the identification of the most vulnerable stages of life and the optimum window of opportunity
for intervention.
5. Conclusions
The results of this systematic review support the beneficial effects of DHA supplementation in
PKU patients: deficient LC-PUFA status is corrected in patients from 2 weeks to 47 years of age, and
P100 wave latency improves in children from 1 to 11 years old. However, evidence is inconclusive
regarding the effect of DHA on neurocognitive function. Further research will be required to establish
the optimal DHA dose and duration of intervention.
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